{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:57:06Z","timestamp":1784159826842,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>Hospital-acquired pneumonia (HAP) is the most common hospital-acquired infection, accounting for 22% of all nosocomial infections. The available studies to date have not attempted to assess whether confounding factors may account for the observed difference in mortality for the two forms of nosocomial pneumonia associated with mechanical ventilation, namely ventilated HAP (vHAP) and ventilator-associated pneumonia (VAP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To determine if vHAP is an independent predictor of mortality among patients with nosocomial pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN, SETTING, AND PARTICIPANTS:<\/jats:title>\n            <jats:p>Single-center retrospective cohort study conducted at Barnes-Jewish Hospital, St. Louis, MO, between 2016 and 2019. Adult patients with a pneumonia discharge diagnosis were screened and patients diagnosed with vHAP and VAP were included. All patient data was extracted from the electronic health record.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>The primary outcome was 30-day all-cause mortality (ACM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>One thousand one-hundred twenty unique patient admissions were included (410 vHAP, 710 VAP). Thirty-day ACM was greater for patients with vHAP compared with VAP (37.1% vs 28.5%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.003). Logistic regression analysis identified vHAP (adjusted odds ratio [AOR], 1.77; 95% CI, 1.51\u20132.07), vasopressor use (AOR, 2.34; 95% CI, 1.94\u20132.82), Charlson Comorbidity Index (1-point increments) (AOR, 1.21; 95% CI, 1.18\u20131.24), total antibiotic treatment days (1-d increments) (AOR, 1.13; 95% CI, 1.11\u20131.14), and Acute Physiology and Chronic Health Evaluation II score (1-point increments) (AOR, 1.04; 95% CI, 1.03\u20131.06) as independent predictors of 30-day ACM. The most common bacterial pathogens identified as causes of vHAP and VAP were <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>, <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic> species, and <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>In this single-center cohort study with low rates of initial inappropriate antibiotic therapy, vHAP had greater 30-day ACM compared with VAP after adjusting for potential confounding variables including disease severity and comorbidities. This finding suggests that clinical trials enrolling patients with vHAP need to account for this outcome difference in their trial design and data interpretation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000867","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T18:00:11Z","timestamp":1677261611000},"page":"e0867","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia"],"prefix":"10.1097","volume":"5","author":[{"given":"Hayley","family":"Motowski","sequence":"first","affiliation":[{"name":"Department of Medical Education, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ilges","sequence":"additional","affiliation":[{"name":"Depatment of Pharmacy, Mayo Clinic Hospital, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hampton","sequence":"additional","affiliation":[{"name":"Center for Clinical Excellence, BJC HealthCare, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Micek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO."},{"name":"Department of Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017.","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals.","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"200023","DOI":"10.1183\/16000617.0023-2020","article-title":"Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?","volume":"29","author":"Vallecoccia","year":"2020","journal-title":"Eur Respir Rev"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","article-title":"Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.","volume":"219","author":"Talbot","year":"2019","journal-title":"J Infect Dis"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012\u20132019.","volume":"50","author":"Zilberberg","year":"2022","journal-title":"Crit Care Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2018.10.014","article-title":"Outcomes associated with de-escalating therapy for methicillin-resistant Staphylococcus aureus in culture-negative nosocomial pneumonia.","volume":"155","author":"Cowley","year":"2019","journal-title":"Chest"},{"key":"R8-20240807","first-page":"188","article-title":"Charlson comorbidity index: ICD-9 update and ICD-10 translation.","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury.","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.chest.2016.04.009","article-title":"A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes.","volume":"150","author":"Micek","year":"2016","journal-title":"Chest"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1089\/sur.2017.111","article-title":"A prospective one-year microbiologic survey of combined pneumonia and respiratory failure.","volume":"18","author":"Fisher","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-017-1772-4","article-title":"Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: A cross-over study.","volume":"21","author":"Trupka","year":"2017","journal-title":"Crit Care"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1097\/MD.0000000000004708","article-title":"A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?","volume":"95","author":"Guillamet","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1378\/chest.122.1.262","article-title":"Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.","volume":"122","author":"Iregui","year":"2002","journal-title":"Chest"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/0036554021000026934","article-title":"ICU-acquired nosocomial infection: Impact of delay of adequate antibiotic treatment.","volume":"34","author":"Mathevon","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/CCM.0000000000005297","article-title":"Increased incidence of ventilator-acquired pneumonia in coronavirus disease 2019 patients: A multicentric cohort study.","volume":"50","author":"Vacheron","year":"2022","journal-title":"Crit Care Med"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial.","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-021-03694-3","article-title":"Ceftolozane\/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: Subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.","volume":"25","author":"Timsit","year":"2021","journal-title":"Crit Care"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:16:07Z","timestamp":1723029367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000867","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}